SCHEMBL3498797

SCHEMBL3498797

CCOC(=O)CNC(=O)c1oc2cc(-c3ccc(Cl)cc3)ccc2c1C

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 1/20 0.46
MAPT P10636 6/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
HIF1A Q16665 1/20 0.42
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
RAB9A P51151 1/20 0.41
BRCA1 P38398 1/20 0.41
TP53 P04637 1/20 0.41
THRB P10828 1/20 0.41
CASP1 P29466 2/20 0.41
KDM4E B2RXH2 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5275062 0.89 MCL1 (0.44) MCL1MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL3499188 0.88 MAPT (0.41) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL3500040 0.86 MCL1 (0.53) MCL1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL3499722 0.83 HIF1A (0.55) MCL1MAPTALDH1A1SMN1; SMN2HIF1A
SCHEMBL3498799 0.80 MCL1 (0.51) MCL1MAPTLMNASMN1; SMN2KMT2A
SCHEMBL3500451 0.79 HDAC1 (0.46) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL5271564 0.78 NPSR1 (0.40) MCL1MAPTLMNAALDH1A1SMN1; SMN2
SCHEMBL3499402 0.76 PPID (0.41) MCL1MAPTLMNAALDH1A1HIF1A
SCHEMBL3498970 0.76 MCL1 (0.40) MCL1MAPTLMNASMN1; SMN2HIF1A
SCHEMBL3499404 0.76 PPID (0.41) MCL1MAPTLMNAALDH1A1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-27 US disclosed
EP-1849465-A1 AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR Takeda Pharmaceutical Company Limited (JP) 2007-10-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130737-A1 Regulating Agent of GPR34 Receptor Function GPR34, GPR4, GPR6 MCL1 3727/4885MAPT 4820/4885LMNA 4645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.